Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369220 · ClinicalTrials.gov registry record · NA
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
A NA study of Neisseria Gonorrhoeae Infection and Chlamydia Trachomatis Infection, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
- 344
- Enrollment target
- 4
- Study locations
NCT06369220 is a NA study of Neisseria Gonorrhoeae Infection and Chlamydia Trachomatis Infection that has completed, run by Hoffmann-La Roche. The registered enrollment target is 344 participants, below the 1,624-participant average among 3 other Neisseria Gonorrhoeae Infection trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06369220, a NA study of Neisseria Gonorrhoeae Infection and Chlamydia Trachomatis Infection, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
- 344 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST cobas® liat CT/NG/MG nucleic acid test
- OTHER Standard of Care (SOC): Clinician's Standard Practice
Study Locations (4)
New Jersey
- Planned Parenthood of Northern, Central, and Southern New Jersey, Inc. - Hamilton Square
- Planned Parenthood of Northern, Central and Southern New Jersey - Perth Amboy
California
- San Francisco City Clinic - San Francisco
Texas
- Baylor Scott & White Health - Kileen - Killeen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2025-05-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06369220
The ClinicalTrials.gov registry entry for NCT06369220 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,624-participant average among 3 other Neisseria Gonorrhoeae Infection trials with a reported enrollment target (79% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neisseria Gonorrhoeae Infection appearing as the primary indexed condition, and to 2 interventions - of which cobas® liat CT/NG/MG nucleic acid test is the first listed.
NCT06369220 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06369220 about?
NCT06369220 is a clinical study titled "A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections". This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).
What is the current status of trial NCT06369220?
This trial is currently completed. It is a NA study. The enrollment target is 344 participants. The study started on 2024-07-29. Estimated completion is 2025-05-28.
What conditions does trial NCT06369220 study?
This clinical trial studies the following conditions: Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection, Mycoplasma Genitalium Infection.
What interventions are being tested in trial NCT06369220?
The interventions under investigation include: cobas® liat CT/NG/MG nucleic acid test (DIAGNOSTIC_TEST), Standard of Care (SOC): Clinician's Standard Practice (OTHER).
Who is sponsoring clinical trial NCT06369220?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06369220 being conducted?
This trial has 4 study locations across California, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neisseria Gonorrhoeae Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
RECRUITING · NA
-
Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT
COMPLETED · NA
-
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
COMPLETED
Explore more on PlainTrial
Neisseria Gonorrhoeae Infection
All registered trials for this condition
Chlamydia Trachomatis Infection
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.